While the RPTD and MTD were not formally established, our findings suggest that an anti-CD37 antibody may be combined with ibrutinib, or potentially other BTK inhibitors, for the treatment of relapsed/refractory CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.